000 | 01660nam a22002537a 4500 | ||
---|---|---|---|
999 |
_c7994 _d7994 |
||
001 | CH 2008 0001 | ||
003 | PILC | ||
005 | 20240720152609.0 | ||
008 | 160505b2008 xxu||||| |||| 00| 0 eng d | ||
040 |
_beng _cFEU-NRMF MEDICAL LIBRARY _erda |
||
041 | _aenglish | ||
050 | _aCH 2008 0001 | ||
245 |
_aAcute myelogenous leukemia a case report / _cMa. Flora Y. Redor. |
||
260 |
_aFairview, Quezon City: _bDepartment of Child Heath, FEU-NRMF, _c2008. |
||
300 |
_a21 pages: _btables; _c(in folder) |
||
336 |
_atext _2rdacontent |
||
337 |
_aunmediated _2rdamedia |
||
338 |
_avolume _2rdacarrier |
||
504 | _aIncludes appendices and bibliographical references. | ||
520 | _aAbstract: A Case of a 15 year old, female with history of fever, constipation, black tarry stools, anemia malaise, easy fatigability and headache is presented. Acute myelogenous leukemia (AML) French American British (FAB) M3 classification was confirmed by bone marrow biopsy. The myelogenous leukemia are heterogenous group of disease characterized by infiltration of the blood, bone marrow and other tissues by neoplastic cells of the hematopoietic system. AML accounts for 11% of the cases of childhood leukemia in the USA, with approximately 370 children diagnosed with AML annually. In the Philippines, it ranks 5th among the killer diseases. Despite all ongoing efforts to improve treatment and supportive care, childhood AML still remains a challenging disease. The current 5-year survival rate approaches 50% with the use of intensive-timing chemotherapy (CCG 2891). | ||
521 | _aRESDCH | ||
700 |
_aRedor, Ma. Flora Y., MD. _eauthor |
||
942 |
_2lcc _cRU |